Cargando…

First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab

The CD52-targeting antibody alemtuzumab is established in clinical practice with convincing activity in relapsed and refractory chronic lymphocytic leukemia (CLL), particularly in patients with high-risk features and adverse prognosis. In the CAM307 study alemtuzumab was tested and finally approved...

Descripción completa

Detalles Bibliográficos
Autores principales: Schweighofer, Carmen Diana, Wendtner, Clemens-Martin
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2895774/
https://www.ncbi.nlm.nih.gov/pubmed/20616957
_version_ 1782183288967790592
author Schweighofer, Carmen Diana
Wendtner, Clemens-Martin
author_facet Schweighofer, Carmen Diana
Wendtner, Clemens-Martin
author_sort Schweighofer, Carmen Diana
collection PubMed
description The CD52-targeting antibody alemtuzumab is established in clinical practice with convincing activity in relapsed and refractory chronic lymphocytic leukemia (CLL), particularly in patients with high-risk features and adverse prognosis. In the CAM307 study alemtuzumab was tested and finally approved as a first-line single agent, even though the hurdle with chlorambucil as the contender was not set very high. Within clinical trials, the drug demonstrated an excellent ability to eliminate minimal residual disease in blood and bone marrow, which has been correlated with a corresponding survival advantage in patients. However, in the maintenance setting, infectious complications due to severe T cell suppression have been highlighted and do not allow clinicans to use alemtuzumab outside of clinical trials. This review discusses potential therapeutic niches and future applications of alemtuzumab with a focus on CLL front-line treatment.
format Text
id pubmed-2895774
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-28957742010-07-08 First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab Schweighofer, Carmen Diana Wendtner, Clemens-Martin Onco Targets Ther Review The CD52-targeting antibody alemtuzumab is established in clinical practice with convincing activity in relapsed and refractory chronic lymphocytic leukemia (CLL), particularly in patients with high-risk features and adverse prognosis. In the CAM307 study alemtuzumab was tested and finally approved as a first-line single agent, even though the hurdle with chlorambucil as the contender was not set very high. Within clinical trials, the drug demonstrated an excellent ability to eliminate minimal residual disease in blood and bone marrow, which has been correlated with a corresponding survival advantage in patients. However, in the maintenance setting, infectious complications due to severe T cell suppression have been highlighted and do not allow clinicans to use alemtuzumab outside of clinical trials. This review discusses potential therapeutic niches and future applications of alemtuzumab with a focus on CLL front-line treatment. Dove Medical Press 2010-06-24 /pmc/articles/PMC2895774/ /pubmed/20616957 Text en © 2010 Schweighofer and Wendtner, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Schweighofer, Carmen Diana
Wendtner, Clemens-Martin
First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab
title First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab
title_full First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab
title_fullStr First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab
title_full_unstemmed First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab
title_short First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab
title_sort first-line treatment of chronic lymphocytic leukemia: role of alemtuzumab
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2895774/
https://www.ncbi.nlm.nih.gov/pubmed/20616957
work_keys_str_mv AT schweighofercarmendiana firstlinetreatmentofchroniclymphocyticleukemiaroleofalemtuzumab
AT wendtnerclemensmartin firstlinetreatmentofchroniclymphocyticleukemiaroleofalemtuzumab